AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these ...

AbbVie's positioning in this niche is intact thanks to its superstar products like Rinvoq, Skyrizi, and Humira. Humira has been dominating the space for almost two decades until its patent expired ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...

Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian tariffs and has increased its dividend for 30 consecutive years.

However, the company appears to be forging a clear path for post-Humira growth. Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to ...

The company’s flagship product, Humira, is widely used to treat autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, plaque psoriasis, and ulcerative colitis. AbbVie Inc. (NYSE ...